Company intelligence / Profile preview

Nu-Life Solutions

Not explicitly stated but global operations including United States.nu-v3.com ↗

Ownership: Private
Employees: ~23
Development stage: Commercial

Overview

Nu-Life Solutions has developed the Nu-V3 device—a miniaturized, wearable, non-invasive neuromodulation technology for treating symptoms of pain, anxiety, depression, and sleeplessness. The device is patented in over 40 countries. It offers a non-pharmaceutical alternative to traditional treatments for these conditions. No clinical trial data or peer-reviewed results are publicly detailed.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapyWearable neuromodulation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Nu-V3

Commercial

Indications: Pain, Anxiety, Depression, Sleep disorders

Beyond the preview

Go deeper on Nu-Life Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nu-Life Solutions.

Explore the full profile